The NR1I3 antibody is designed to target the nuclear receptor subfamily 1. group I, member 3 (NR1I3), commonly known as the constitutive androstane receptor (CAR). CAR is a ligand-activated transcription factor primarily expressed in the liver and intestine, playing a critical role in regulating genes involved in drug metabolism, energy homeostasis, and detoxification. It forms heterodimers with the retinoid X receptor (RXR) to bind specific DNA response elements, modulating the expression of cytochrome P450 enzymes (e.g., CYP2B, CYP3A) and transporters (e.g., MRP2). CAR is activated by diverse xenobiotics and endogenous compounds, influencing drug-drug interactions, bilirubin clearance, and bile acid homeostasis. Dysregulation of CAR has been implicated in liver diseases, metabolic disorders, and cancer.
NR1I3 antibodies are essential tools for studying CAR's expression, localization, and function in both physiological and pathological contexts. These antibodies, typically raised in rabbits or mice, enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Validated antibodies help assess CAR levels in tissue samples, cell lines, or animal models, particularly in studies exploring drug-induced hepatotoxicity, cholestasis, or metabolic reprogramming in tumors. Specificity is confirmed using knockout controls or competitive assays. By facilitating CAR-related research, NR1I3 antibodies contribute to understanding its role in disease mechanisms and therapeutic targeting, bridging gaps between basic science and clinical applications.